Docoh
Loading...

AMPE Ampio Pharmaceuticals

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On August 14, 2021, Ampio Pharmaceuticals, Inc. (the “Company”), held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The number of shares of common stock entitled to vote at the Annual Meeting was 196,847,146. The number of shares of common stock present, in person or represented by proxy, and entitled to vote at the Annual Meeting was 107,446,464.



The certified results of each of the matters voted upon at the Annual Meeting, which are more fully described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 30, 2021 (the “Proxy Statement”), are as follows:



(1) The following nominees were elected as directors, each to hold office until the Company’s 2022 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or their earlier resignation or removal:

NomineesForWithheldBroker Non-Votes
Michael Macaluso45,023,5436,775,12055,647,801
David Bar-Or, M.D.49,709,4792,089,18455,647,801
Philip H. Coelho43,669,2308,129,43355,647,801
Richard B. Giles44,254,3527,544,31155,647,801
David R. Stevens, Ph.D.44,579,4707,219,19355,647,801


(2) The selection of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 was ratified by the vote set forth below:

ForAgainstAbstainBroker Non-Votes
103,717,2891,451,3932,277,7820




(3) The compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, was approved on an advisory (non-binding) basis, by the vote set forth below:

ForAgainstAbstainBroker Non-Votes
38,433,42411,590,8571,774,38255,647,801


.